Study Evaluating the Safety, Immunogenicity and Tolerability of Meningococcal Group B Vaccine in Healthy Adults
Phase 1
Completed
- Conditions
- Meningitis, Meningococcal
- Registration Number
- NCT00297687
- Lead Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Brief Summary
To determine the safety \& immunogenicity of a potential vaccine against meningococcal B disease
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 108
Inclusion Criteria
- Healthy 18-25 year olds
Exclusion Criteria
- Prior history of vaccination with any meningococcal vaccine
- Prior history of any invasive meningococcal disease
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Local & systemic safety throughout the trial
- Secondary Outcome Measures
Name Time Method Evidence of an immune response 1 month after dose 2 & 1 month after dose 3